Algal oil is most commonly used along with another fatty acid to fortify infant formula. It is also used for improving thinking skills in children and older people, lowering cholesterol, improving vision in people with a certain eye condition (retinitis pigmentosa), and many other conditions, but there is no good scientific evidence to support these uses.
Don't confuse algal oil with algae such as blue-green algae, brown algae, chlorella, or laminaria. Also, don't confuse algal oil with DHA or EPA from other sources such as fish oil.
How does it work ?
Uses & Effectiveness ?
Possibly Ineffective for
- Memory and thinking skills (cognitive function). Taking algal oil does not seem to improve cognitive function or reading ability in most children.
Insufficient Evidence for
- Decline in memory and thinking skills that occurs normally with age. Some research shows that taking algal oil can improve an older person's ability to remember past events. It also seems to improve some forms of learning. But taking algal oil doesn't seem to improve short-term memory related to reasoning and decision-making in older people. And it doesn't seem to improve higher-level thinking skills.
- A lung disease that affects newborns (bronchopulmonary dysplasia). Some research shows that giving algal oil rich in DHA to breast-feeding mothers doesn't reduce a preterm infant's risk for this lung disease. It might even increase the risk for this disease in some infants.
- Child development. Taking algal oil while breastfeeding doesn't seem to improve vision of the breastfed infant by the age of 4 or 8 months. It also doesn't seem to improve most measures of brain development in the child by the age of 5 years. But it might improve motor skills in the child by the age of 30 months and attention at the age of 5 years.
- Heart disease. Eating 1.5 tablespoons per day of an algal oil that is high in oleic acid may help to prevent heart disease. But research is limited.
- High levels of cholesterol or other fats (lipids) in the blood (hyperlipidemia). Taking algal oil rich in DHA might help lower blood fats called triglycerides. It might also increase high-density lipoprotein (HDL, or "good") cholesterol. But taking algal oil seems to also increase low-density lipoprotein (LDL, or "bad") cholesterol. Most research has involved patients without heart disease. So it's unclear if algal oil rich in DHA can improve cholesterol or reduce the risk of heart-related events in people with heart disease. Taking algal oil rich in EPA does not seem to lower triglycerides or LDL cholesterol.
- A serious intestinal disease in premature infants (necrotizing enterocolitis or NEC). Early research suggests that taking algal oil providing DHA while breast-feeding does not prevent NEC in preterm infants.
- Low bone mass (osteopenia). Early research shows that taking algal oil along with calcium and vitamin D doesn't improve bone mass better than taking just calcium and vitamin D.
- An inherited eye condition that causes poor night vision and loss of side vision (retinitis pigmentosa). Taking algal oil doesn't seem to slow the breakdown of cells in the retina in males with this eye condition. The breakdown of these cells can lead to loss of side vision and difficulty seeing at night. But taking algal oil might slow the loss of visual field sensitivity.
- An eye disorder in premature infants that can lead to blindness (retinopathy of prematurity). Early research suggests that taking algal oil providing DHA while breast-feeding does not prevent retinopathy of prematurity in preterm infants.
- Blood infection (sepsis). Early research suggests that taking algal oil containing DHA while breast-feeding does not prevent sepsis in preterm infants.
- Cystic fibrosis.
- Infant development.
- Other conditions.
Most side effects of algal oil are mild and may include fishy burps, stomach or intestine symptoms, or slightly increased cholesterol levels. But algal oil is a source of the omega-3 fatty acids DHA and EPA. Doses of algal oil providing DHA and EPA in excess of 3 grams per day is POSSIBLY UNSAFE. There is concern that taking more than 3 grams per day of EPA and DHA might slow blood clotting and may increase the chance of bleeding. People should limit their intake of DHA and EPA to no more than 3 grams per day, with no more than 2 grams per day from a dietary supplement.
Special Precautions and Warnings
Infants and children: Algal oil rich in docosahexaenoic acid (DHA) is LIKELY SAFE when used appropriately. Algal oil is included as a source of DHA in some infant formula. It is generally recognized as safe for this use. Algal oil has also been used safely for up to 4 years in children 7 years and older in daily doses that provide 30 mg/kg of the omega-3 fatty acid DHA. There isn't enough reliable information to know if algal oil rich in eicosapentaenoic acid (EPA) is safe to use in infants and children. Stay on the safe side and avoid use.
Aspirin-sensitivity: Some algal oil contains DHA. DHA might affect your breathing if you are sensitive to aspirin.
Bleeding conditions: Some algal oil contains the omega-3 fatty acids DHA and EPA. DHA alone does not seem to affect blood clotting. However, there is concern that taking algal oil in doses providing more than 3 grams per day of EPA and DHA might increase the risk of bleeding.
Difficulty breathing in preterm infants: Some algal oil contains DHA. DHA might worsen breathing in preterm infants who already have difficulty breathing.
Diabetes: Some algal oil contains DHA. DHA might increase pre-meal blood sugar in people with type 2 diabetes.
Low blood pressure: Some algal oil contains DHA. DHA can lower blood pressure. This might increase the risk of blood pressure becoming too low in people who already have low blood pressure.
We currently have no information for ALGAL OIL overview.
Arterburn, L. M., Oken, H. A., Bailey, Hall E., Hamersley, J., Kuratko, C. N., and Hoffman, J. P. Algal-oil capsules and cooked salmon: nutritionally equivalent sources of docosahexaenoic acid. J Am Diet Assoc 2008;108(7):1204-1209. View abstract.
Arterburn, L. M., Oken, H. A., Hoffman, J. P., Bailey-Hall, E., Chung, G., Rom, D., Hamersley, J., and McCarthy, D. Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food. Lipids 2007;42(11):1011-1024. View abstract.
Bazan, N. G. Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci 2006;29(5):263-271. View abstract.
Bazan, N. G. Homeostatic regulation of photoreceptor cell integrity: significance of the potent mediator neuroprotectin D1 biosynthesized from docosahexaenoic acid: the Proctor Lecture. Invest Ophthalmol Vis.Sci 2007;48(11):4866-4881. View abstract.
Bazan, N. G. Neurotrophins induce neuroprotective signaling in the retinal pigment epithelial cell by activating the synthesis of the anti-inflammatory and anti-apoptotic neuroprotectin D1. Adv.Exp Med Biol 2008;613:39-44. View abstract.
Clandinin, M. T., Van Aerde, J. E., Merkel, K. L., Harris, C. L., Springer, M. A., Hansen, J. W., and Diersen-Schade, D. A. Growth and development of preterm infants fed infant formulas containing docosahexaenoic acid and arachidonic acid. J Pediatr 2005;146(4):461-468. View abstract.
Clandinin, M. T., Van Aerde, J. E., Parrott, A., Field, C. J., Euler, A. R., and Lien, E. L. Assessment of the efficacious dose of arachidonic and docosahexaenoic acids in preterm infant formulas: fatty acid composition of erythrocyte membrane lipids. Pediatr Res 1997;42(6):819-825. View abstract.
Engler, M. M., Engler, M. B., Malloy, M. J., Paul, S. M., Kulkarni, K. R., and Mietus-Snyder, M. L. Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study). Am J Cardiol 4-1-2005;95(7):869-871. View abstract.
Horrocks, L. A. and Farooqui, A. A. Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot.Essent.Fatty Acids 2004;70(4):361-372. View abstract.
Jensen, C. L., Voigt, R. G., Llorente, A. M., Peters, S. U., Prager, T. C., Zou, Y. L., Rozelle, J. C., Turcich, M. R., Fraley, J. K., Anderson, R. E., and Heird, W. C. Effects of early maternal docosahexaenoic acid intake on neuropsychological status and visual acuity at five years of age of breast-fed term infants. J Pediatr 2010;157(6):900-905. View abstract.
Jensen, C. L., Voigt, R. G., Prager, T. C., Zou, Y. L., Fraley, J. K., Rozelle, J. C., Turcich, M. R., Llorente, A. M., Anderson, R. E., and Heird, W. C. Effects of maternal docosahexaenoic acid intake on visual function and neurodevelopment in breastfed term infants. Am J Clin Nutr 2005;82(1):125-132. View abstract.
Kelley, D. S., Siegel, D., Vemuri, M., and Mackey, B. E. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr 2007;86(2):324-333. View abstract.
Kroes, R., Schaefer, E. J., Squire, R. A., and Williams, G. M. A review of the safety of DHA45-oil. Food Chem Toxicol. 2003;41(11):1433-1446. View abstract.
Lien, E. L. Toxicology and safety of DHA. Prostaglandins Leukot.Essent.Fatty Acids 2009;81(2-3):125-132. View abstract.
Lloyd-Still, J. D., Powers, C. A., Hoffman, D. R., Boyd-Trull, K., Lester, L. A., Benisek, D. C., and Arterburn, L. M. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition 2006;22(1):36-46. View abstract.
Maki, K. C., Van Elswyk, M. E., McCarthy, D., Hess, S. P., Veith, P. E., Bell, M., Subbaiah, P., and Davidson, M. H. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr 2005;24(3):189-199. View abstract.
McNamara, R. K., Able, J., Jandacek, R., Rider, T., Tso, P., Eliassen, J. C., Alfieri, D., Weber, W., Jarvis, K., DelBello, M. P., Strakowski, S. M., and Adler, C. M. Docosahexaenoic acid supplementation increases prefrontal cortex activation during sustained attention in healthy boys: a placebo-controlled, dose-ranging, functional magnetic resonance imaging study. Am J Clin Nutr 2010;91(4):1060-1067. View abstract.
Michael-Titus, A. T. Omega-3 fatty acids and neurological injury. Prostaglandins Leukot.Essent.Fatty Acids 2007;77(5-6):295-300. View abstract.
Mori, T. A., Bao, D. Q., Burke, V., Puddey, I. B., and Beilin, L. J. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 1999;34(2):253-260. View abstract.
Nestel, P., Shige, H., Pomeroy, S., Cehun, M., Abbey, M., and Raederstorff, D. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am.J.Clin.Nutr. 2002;76(2):326-330. View abstract.
Ryan, A. S., Keske, M. A., Hoffman, J. P., and Nelson, E. B. Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors. Am J Ther 2009;16(2):183-192. View abstract.
Sanders, T. A., Gleason, K., Griffin, B., and Miller, G. J. Influence of an algal triacylglycerol containing docosahexaenoic acid (22 : 6n-3) and docosapentaenoic acid (22 : 5n-6) on cardiovascular risk factors in healthy men and women. Br J Nutr 2006;95(3):525-531. View abstract.
Siddiqui, R. A., Harvey, K., and Stillwell, W. Anticancer properties of oxidation products of docosahexaenoic acid. Chem Phys Lipids 2008;153(1):47-56. View abstract.
Siddiqui, R. A., Shaikh, S. R., Sech, L. A., Yount, H. R., Stillwell, W., and Zaloga, G. P. Omega 3-fatty acids: health benefits and cellular mechanisms of action. Mini.Rev Med Chem 2004;4(8):859-871. View abstract.
Sublette, M. E., Ellis, S. P., Geant, A. L., and Mann, J. J. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J.Clin.Psychiatry 2011;72(12):1577-1584. View abstract.
Theobald, H. E., Chowienczyk, P. J., Whittall, R., Humphries, S. E., and Sanders, T. A. LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women. Am.J.Clin.Nutr. 2004;79(4):558-563. View abstract.
Theobald, H. E., Goodall, A. H., Sattar, N., Talbot, D. C., Chowienczyk, P. J., and Sanders, T. A. Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women. J Nutr 2007;137(4):973-978. View abstract.
Woodman, R. J., Mori, T. A., Burke, V., Puddey, I. B., Barden, A., Watts, G. F., and Beilin, L. J. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 2003;166(1):85-93. View abstract.
Wu, W. H., Lu, S. C., Wang, T. F., Jou, H. J., and Wang, T. A. Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women. Eur J Clin Nutr 2006;60(3):386-392. View abstract.
Zucker, M. L., Bilyeu, D. S., Helmkamp, G. M., Harris, W. S., and Dujovne, C. A. Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects. Atherosclerosis 1988;73(1):13-22. View abstract.
99110 Collins ML, Lynch B, Barfield W, Bull A, Ryan AS, Astwood JD. Genetic and acute toxicological evaluation of an algal oil containing eicosapentaenoic acid (EPA) and palmitoleic acid. Food Chem Toxicol. 2014;72:162-8. View abstract.
Alicandro G, Faelli N, Gagliardini R, Santini B, Magazzù G, Biffi A, Risé P, Galli C, Tirelli AS, Loi S, Valmarana L, Cirilli N, Palmas T, Vieni G, Bianchi ML, Agostoni C, Colombo C. A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis.Prostaglandins Leukot Essent Fatty Acids. 2013 Feb;88(2):163-9. view abstract.
Aussant J, Guihéneuf F, Stengel DB. Impact of temperature on fatty acid composition and nutritional value in eight species of microalgae. Appl Microbiol Biotechnol. 2018;102(12):5279-5297. View abstract.
Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012 Oct 1;110(7):984-92. View abstract.
Bernstein AM, Ding EL, Willett WC, Rimm EB. A meta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease. J Nutr. 2012;142(1):99-104. View abstract.
Birch EE, Garfield S, Hoffman DR, et al. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev Med Child Neurol 2000;42:174-81. View abstract.
Breastfeeding and the use of human milk. Section on Breastfeeding. Pediatrics. 2012;129(3):e827-41. View abstract.
Burns RA, Wibert GJ, Diersen-Schade DA, Kelly CM. Evaluation of single-cell sources of docosahexaenoic acid and arachidonic acid: 3-month rat oral safety study with an in utero phase. Food Chem Toxicol. 1999;37(1):23-36. View abstract.
Calder PC. N-3 polyunsaturated fatty acids, inflammation and immunity: pouring oil on troubled waters or another fishy tale? Nutr Res 2001;21:309-41.
Carlson SE, Colombo J, Gajewski BJ, Gustafson KM, Mundy D, Yeast J, Georgieff MK, Markley LA, Kerling EH, Shaddy DJ. DHA supplementation and pregnancy outcomes. Am J Clin Nutr. 2013 Apr;97(4):808-15. View abstract.
Connor WE. n-3 Fatty acids from fish and fish oil: panacea or nostrum? Am J Clin Nutr 2001;74;415-6. View abstract.
Deng Q, Wang Y, Wang C, et al. Dietary supplementation with omega-3 polyunsaturated fatty acid-rich oils protects against visible-light-induced retinal damage in vivo. Food Funct. 2018;9(4):2469-2479. View abstract.
Doi M, Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa K, Nakayama R, Takagi W, Takeda K, Hirohata S, Ito H. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. Int J Cardiol. 2014 Oct 20;176(3):577-82. View abstract.
Erkkila AT, Lehto S, Pyorala K, Uusitupa MI. n-3 Fatty acids and 5-y risks of death and cardiovascular disease events in patients with coronary artery disease. Am J Clin Nutr 2003;78:65-71.. View abstract.
FDA announces qualified health claims for omega-3 fatty acids. Available at: https://www.fda.gov/Food/LabelingNutrition/ucm072756.htm. Accessed April 15 2019.
FDA completes review of qualified health claim petition for oleic acid and the risk of coronary heart disease. November 2018. Available at: www.fda.gov/Food/NewsEvents/ConstituentUpdates/ucm624758.htm. Accessed January 25, 2019.
FDA. Center for Food Safety and Applied Nutrition. Letter regarding dietary supplement health claim for omega-3 fatty acids and coronary heart disease. Available at: https://www.fda.gov/ohrms/dockets/dockets/95s0316/95s-0316-Rpt0272-38-Appendix-D-Reference-F-FDA-vol205.pdf. (Accessed February 7, 2017).
Fernandez-Jarne E, Martinez-Losa E, Prado-Santamaria M, et al. Risk of first non-fatal myocardial infarction negatively associated with olive oil consumption: a case-control study in Spain. Int J Epidemiol 2002;31:474-80. View abstract.
Finnegan YE, Howarth D, Minihane AM, et al. Plant and marine derived (n-3) polyunsaturated fatty acids do not affect blood coagulation and fibrinolytic factors in moderately hyperlipidemic humans. J Nutr 2003;133:2210-3.. View abstract.
Fu YQ, Zheng JS, Yang B, Li D. Effect of individual omega-3 fatty acids on the risk of prostate cancer: a systematic review and dose-response meta-analysis of prospective cohort studies. J Epidemiol. 2015;25(4):261-74. View abstract.
Gibson RA. Long-chain polyunsaturated fatty acids and infant development (editorial). Lancet 1999;354:1919.
Goodnight SH Jr, Harris WS, Connor WE. The effects of dietary omega 3 fatty acids on platelet composition and function in man: a prospective, controlled study. Blood. 1981 Nov;58(5):880-5. View abstract.
Grimsgaard S, Bonaa KH, Hansen JB, Nordoy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr 1997;66:649-59. View abstract.
Hadley KB, Bauer J, Milgram NW. The oil-rich alga Schizochytrium sp. as a dietary source of docosahexaenoic acid improves shape discrimination learning associated with visual processing in a canine model of senescence. Prostaglandins Leukot Essent Fatty Acids. 2017;118:10-18. View abstract.
Hammond BG, Mayhew DA, Naylor MW, Ruecker FA, Mast RW, Sander WJ. Safety assessment of DHA-rich microalgae from Schizochytrium sp. Regul Toxicol Pharmacol. 2001;33(2):192-204. View abstract.
Hoffman D, Ziegler E, Mitmesser SH, Harris CL, Diersen-Schade DA. Soy-based infant formula supplemented with DHA and ARA supports growth and increases circulating levels of these fatty acids in infants. Lipids. 2008;43(1):29-35. View abstract.
Hoffman DR, Hughbanks-Wheaton DK, Pearson NS, Fish GE, Spencer R, Takacs A, Klein M, Locke KG, Birch DG. Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial. JAMA Ophthalmol. 2014 Jul;132(7):866-73. View abstract.
Hoffman DR, Hughbanks-Wheaton DK, Spencer R, et al. Docosahexaenoic Acid Slows Visual Field Progression in X-Linked Retinitis Pigmentosa: Ancillary Outcomes of the DHAX Trial. Invest Ophthalmol Vis Sci. 2015;56(11):6646-53. View abstract.
Hughbanks-Wheaton DK, Birch DG, Fish GE, Spencer R, Pearson NS, Takacs A, Hoffman DR. Safety assessment of docosahexaenoic acid in X-linked retinitis pigmentosa: the 4-year DHAX trial. Invest Ophthalmol Vis Sci. 2014 Jul 11;55(8):4958-66. View abstract.
Jones PJ, Senanayake VK, Pu S, Jenkins DJ, Connelly PW, Lamarche B, Couture P, Charest A, Baril-Gravel L, West SG, Liu X, Fleming JA, McCrea CE, Kris-Etherton PM. DHA-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial. Am J Clin Nutr. 2014 Jul;100(1):88-97. View abstract.
Kagan ML, West AL, Zante C, Calder PC. Acute appearance of fatty acids in human plasma--a comparative study between polar-lipid rich oil from the microalgae Nannochloropsis oculata and krill oil in healthy young males. Lipids Health Dis. 2013;12:102. View abstract.
Katan MB, Zock PL, Mensink RP. Dietary oils, serum lipoproteins, and coronary heart disease. Am J Clin Nutr 1995;61:1368S-73S. View abstract.
Keys A, Menotti A, Karvonen MJ , et al. The diet and 15-year death rate in the seven countries study. Am J Epidemiol 1986;124:903-15. View abstract.
Kimura S, Tamayama M, Minami M, et al. Docosahexaenoic acid inhibits blood viscosity in stroke-prone spontaneously hypertensive rats. Res Commun Mol Pathol Pharmacol 1998;100:351-61.. View abstract.
Kleiner AC, Cladis DP, Santerre CR. A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States. J Sci Food Agric. 2015;95(6):1260-7. View abstract.
Kris-Ehterton PM, Harris WS, Appel LJ, et al. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57. View abstract.
Leaf A. On the reanalysis of the GISSI-Prevenzione. Circulation 2002;105:1874-5. View abstract.
Leng GC, Smith FB, Fowkes FG, et al. Relationship between plasma essential fatty acids and smoking, serum lipids, blood pressure and haemostatic and rheological factors. Prostaglandins Leukot Essent Fatty Acids 1994;51:101-8. View abstract.
Lucas A, Stafford M, Morley R, et al. Efficacy and safety of long-chain polyunsaturated fatty acid supplementation of infant-formula milk: a randomized trial. Lancet 1999;354:1948-54. View abstract.
Marangell LB, Martinez JM, Zboyan HA, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003;160:996-8.. View abstract.
Marc I, Piedboeuf B, Lacaze-Masmonteil T, et al. Effect of maternal docosahexaenoic acid supplementation on bronchopulmonary dysplasia-free survival in breastfed preterm infants: A randomized clinical trial. JAMA. 2020;324(2):157-167. View abstract.
Matulka RA, Chan T, Green R, Carney JR, Franklin S, Licari P. 13-week dietary study and in vitro and in vivo genotoxicity studies of a structuring fat produced through a microalgal fermentation process. Toxicol Rep. 2015;3:123-134. View abstract.
Mayser P, Mrowietz U, Arenberger P, et al. Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial. J Am Acad Dermatol 1998;38:539-47. View abstract.
Mischoulon D, Best-Popescu C, Laposata M, et al. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol. 2008;18(9):639-645. View abstract.
Montgomery P, Spreckelsen TF, Burton A, Burton JR, Richardson AJ. Docosahexaenoic acid for reading, working memory and behavior in UK children aged 7-9: A randomized controlled trial for replication (the DOLAB II study). PLoS One. 2018;13(2):e0192909. View abstract.
Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000;71:1085-94. View abstract.
Moriguchi T, Greiner RS, Salem N Jr. Behavioral deficits associated with dietary induction of decreased brain docosahexaenoic acid concentration. J Neurochem 2000;75:2563-73. View abstract.
Mulder KA, King DJ, Innis SM. Omega-3 fatty acid deficiency in infants before birth identified using a randomized trial of maternal DHA supplementation in pregnancy. PLoS One. 2014 Jan 10;9(1):e83764. View abstract.
Nauroth JM, Liu YC, Van Elswyk M, Bell R, Hall EB, Chung G, Arterburn LM. Docosahexaenoic acid (DHA) and docosapentaenoic acid (DPAn-6) algal oils reduce inflammatory mediators in human peripheral mononuclear cells in vitro and paw edema in vivo. Lipids. 2010;45(5):375-84. View abstract.
Nelson GJ, Schmidt PS, Bartolini GL, et al. The effect of dietary docosahexaenoic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. Lipids 1997;32:1129-36. View abstract.
Pedersen HS, Mulvad G, Seidelin KN, et al. N-3 fatty acids as a risk factor for haemorrhagic stroke. Lancet 1999;353:812-3. View abstract.
Picado C, Castillo JA, Schinca N, et al. Effects of a fish oil enriched diet on aspirin intolerant asthmatic patients: a pilot study. Thorax 1988;43:93-7. View abstract.
Prisco D, Paniccia R, Bandinelli B, et al. Effect of medium-term supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients. Thromb Res 1998;1:105-12. View abstract.
Ramakrishnan U, Gonzalez-Casanova I, Schnaas L, DiGirolamo A, Quezada AD, Pallo BC, et al Prenatal supplementation with DHA improves attention at 5 y of age: a randomized controlled trial. Am J Clin Nutr. 2016;104(4):1075-1082. doi.org/10.3945/ajcn.114.101071 View abstract.
Rao A, Briskey D, Nalley JO, Ganuza E. Omega-3 eicosapentaenoic acid (EPA) rich extract from the microalga Nannochloropsis decreases cholesterol in healthy individuals: A double-blind, randomized, placebo-controlled, three-month supplementation study. Nutrients. 2020;12(6):1869. View abstract.
Richardson AJ, Burton JR, Sewell RP, Spreckelsen TF, Montgomery P. Docosahexaenoic acid for reading, cognition and behavior in children aged 7-9 years: a randomized, controlled trial (the DOLAB Study). PLoS One. 2012;7(9):e43909. View abstract.
Sacks FM, Hebert P, Appel LJ, et al. Short report: the effect of fish oil on blood pressure and high-density lipoprotein-cholesterol levels in phase I of the trials of hypertension prevention. J Hypertens 1994;12:209-13. View abstract.
Sánchez-Lara K, Turcott JG, Juárez-Hernández E, Nuñez-Valencia C, Villanueva G, Guevara P, De la Torre-Vallejo M, Mohar A, Arrieta O. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. Clin Nutr. 2014 Dec;33(6):1017-23. View abstract.
Svaneborg N, Kristensen SD, Hansen LM, et al. The acute and short-time effect of supplementation with the combination of n-3 fatty acids and acetylsalicylic acid on platelet function and plasma lipids. Thromb Res 2002;105:311-6. View abstract.
Terano T, Hirai A, Hamazaki T, et al. Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. Atherosclerosis 1983;46:321-31.. View abstract.
Toft I, Bonaa KH, Ingebretsen OC, et al. Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. A randomized, controlled trial. Ann Intern Med 1995;123:911-8. View abstract.
Togna GI, Togna AR, Franconi M, et al. Olive oil isochromans inhibit human platelet reactivity. J Nutr 2003;133:2532-6.. View abstract.
Trevisan M, Krogh V, Freudenheim J, et al. Consumption of olive oil, butter, and vegetable oils and coronary heart disease risk factors. The Research Group ATS-RF2 of the Italian National Research Council. JAMA 1990;263:688-92. View abstract.
van Beelen VA, Roeleveld J, Mooibroek H, et al. A comparative study on the effect of algal and fish oil on viability and cell proliferation of Caco-2 cells. Food Chem Toxicol. 2007;45(5):716-24. View abstract.
Vandongen R, Mori TA, Burke V, et al. Effects on blood pressure of omega 3 fats in subjects at increased risk of cardiovascular disease. Hypertension 1993;22:371-9. View abstract.
Vanlint SJ, Ried K. Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT. Maturitas. 2012;71(1):44-8. View abstract.
von Houwelingen R, Nordøy A, van der Beek E, et al. Effect of a moderate fish intake on blood pressure, bleeding time, hematology, and clinical chemistry in healthy males. Am J Clin Nutr. 1987 Sep;46(3):424-36. View abstract.
Wainwright P. Nutrition and behaviour: the role of n-3 fatty acids in cognitive function. Br J Nutr 2000;83:337-9. View abstract.
Wheaton DH, Hoffman DR, Locke KG, et al. Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa. Arch Ophthalmol 2003;121:1269-78. View abstract.
Woodman RJ, Mori TA, Burke V, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002;76:1007-15.. View abstract.
Yang GY, Wu T, Huang SY, et al. No effect of 6-month supplementation with 300 mg/d docosahexaenoic acid on executive functions among healthy school-aged children: a randomized, double-blind, placebo-controlled trial. Eur J Nutr. 2020. View abstract.
Yao JK, Magan S, Sonel AF, et al. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2004;71:171-6. View abstract.
Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8. View abstract.
Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, Salem N Jr, Stedman M; MIDAS Investigators. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010 Nov;6(6):456-64. View abstract.
Zhang Z, Fulgoni VL, Kris-Etherton PM, Mitmesser SH. Dietary Intakes of EPA and DHA Omega-3 Fatty Acids among US Childbearing-Age and Pregnant Women: An Analysis of NHANES 2001-2014. Nutrients. 2018;10(4). View abstract.